Amplia Therapeutics (ASX: ATX) develops new approach to treat cancer and fibrosis (w/ John Lambert)

Amplia Therapeutics (ASX: ATX) managing director and CEO John Lambert joins Small Caps to discuss the latest results from the company's clinical trial of its lead drug AMP945.The pharmaceutical company is aiming to develop new approaches for the treatment of cancer and fibrosis by advancing a pipeline of focal adhesion kinase (FAK) inhibitors.It recently completed a phase one trial to test the safety and tolerability of AMP945. Amplia now plans to progress to a phase two trial in pancreatic cancer later this year.See omnystudio.com/listener for privacy information.